Bimekizumab Efficacy by Disease Duration and Severity in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results From BE HEARD EXT

Raj Chovatiya,[1,2] Afsaneh Alavi,[3,4] Vivian Y. Shi,[5] Hessel H. van der Zee,[3,6] Melinda Gooderham,[7,8] Takuya Miyagawa,[9] Christos C. Zouboulis,[3,10] Tae Oh,[11] Christina Crater,[12] Nicola Tilt,[13] Robert Sabat[3,14]

[1]Rosalind Franklin University of Medicine and Science Chicago Medical School, North Chicago, IL, USA; [2]Center for Medical Dermatology + Immunology Research, Chicago, IL, USA; [3]European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany; [4]Department of Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; [5]Department of Dermatology, University of Washington, Seattle, USA; [6]Erasmus Medical Center, Rotterdam, The Netherlands; [7]SKiN Centre for Dermatology, Probity Medical Research, Peterborough, ON, Canada; [8]Queen's University, Kingston, ON, Canada; [9]Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan; [10]Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Neuruppin, Germany; [11]UCB, Smyrna, GA, USA; [12]UCB, Morrisville, NC, USA; [13]UCB, Slough, UK; [14]Translational Skin Inflammation Research and Former Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Presentation Number: 73498

Objective

- To assess the achievement of HiSCR50/75/90/100 with bimekizumab (BKZ) treatment across selected disease duration and disease severity subgroups, for patients with moderate to severe hidradenitis suppurativa (HS) from BE HEARD I&II and BE HEARD EXT, over 3 years.

Background

- **Delayed diagnosis** is common for patients with **HS** and may delay treatment; earlier therapeutic intervention may limit disease progression.[1,2]
- Effective treatment within the '**window of opportunity**', when inflammation may be most effectively controlled, is crucial for management of HS.[3,4]
- **BKZ** is a humanized IgG1 monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.[5]

Methods

- Data were pooled from the phase 3 **BE HEARD I&II** trials and their open-label extension, **BE HEARD EXT** (full study design available via QR code), for patients with **moderate to severe HS**.[6,7]
- Patients randomized to receive **BKZ 320 mg** from baseline in BE HEARD I&II who entered BE HEARD EXT were included (**BKZ Total group**).
- Proportions of patients reaching **HiSCR50/75/90/100** up to **Year 3** (Week 148) are reported by:
  - **Lowest disease duration quartile** with **moderate (Hurley stage II) baseline disease severity**;
  - **Highest disease duration quartile** with **severe (Hurley stage III) baseline disease severity**.
- Data are reported as observed case (OC).

1. Saunte DM et al. Br J Dermatol 2015;173:1546–9; **2.** Kokolakis G et al. Dermatol 2020;236:421–30; **3.** Tzellos T et al. Clin Dermatol 2025;43:485–9; **4.** Sabat R et al. Lancet 2025;405:420–38; **5.** Adams R et al. Front Immunol 2020;11:1894; **6.** Kimball AB et al. Lancet 2024;403:2504–19 (NCT04242446, NCT04242498); **7.** BE HEARD EXT (NCT04901195): www.clinicaltrials.gov/study/NCT04901195. BKZ: bimekizumab; HiSCR: HS Clinical Response; HiSCR50/75/90/100: ≥50/75/90/100% reduction from baseline in total abscess and inflammatory nodule count with no increase from baseline in abscess or draining tunnel count; HS: hidradenitis suppurativa; IL: interleukin; OC: observed case.

To receive a copy of this poster, scan the QR code
Link expiration: June 29, 2026

Summary

Patient Subgroups



HiSCR Threshold Achievement at Year 3



Bimekizumab-treated patients with **shorter, moderate HS** demonstrated **higher HiSCR achievement** than those with longer, severe HS.

Baseline Characteristics

	Duration <2.38 years, moderate disease N=85	Duration ≥10.74 years, severe disease N=52
Age (years), mean (SD)	35.4 (14.9)	44.1 (10.6)
Sex, female, n (%)	39 (45.9)	33 (63.5)
Racial group, White, n (%)	69 (81.2)	40 (76.9)
BMI (kg/m²), mean (SD)	30.9 (7.9)	34.0 (7.9)
Smoking status, current, n (%)	31 (36.5)	23 (44.2)
AN count, mean (SD)	13.7 (12.9)	22.5 (15.8)
DT count, mean (SD)	2.4 (2.3)	6.7 (5.6)
DLQI total score, mean (SD)	8.9 (5.7)	14.0 (6.6)
Baseline antibiotic use, n (%)	6 (7.1)	9 (17.3)
Prior biologic use,[a] n (%)	4 (4.7)	15 (28.8)

[**a**] Patients received prior biologic therapy for any indication. AN: abscess and inflammatory nodule; BKZ: bimekizumab; BMI: body mass index; DLQI: Dermatology Life Quality Index; DT: draining tunnel; HiSCR: HS Clinical Response; HiSCR50/75/90/100: ≥50/75/90/100% reduction from baseline in total abscess and inflammatory nodule count with no increase from baseline in abscess or draining tunnel count; HS: hidradenitis suppurativa; OC: observed case.

Patients in Both Subgroups Achieved High Rates of HiSCR50/75 Response Over 3 Years



OC, n/N: denominator represents number of patients with a non-missing lesion count assessment in the given week, and percentages are calculated accordingly. Data are stratified by lowest and highest disease duration quartiles; disease duration is calculated from date of diagnosis of HS. [**a**] Hurley stage II; [**b**] Hurley stage III. BKZ: bimekizumab; HiSCR: HS Clinical Response; HiSCR50/75: ≥50/75% reduction from baseline in total abscess and inflammatory nodule count with no increase from baseline in abscess or draining tunnel count; HS: hidradenitis suppurativa; ITP: initial treatment period; MTP: maintenance treatment period; OC: observed case.

Higher Proportions of Patients With Shorter, Moderate Disease Achieved HiSCR90/100 Versus Patients With Longer, Severe Disease Over 3 Years



OC, n/N: denominator represents number of patients with a non-missing lesion count assessment in the given week, and percentages are calculated accordingly. Data are stratified by lowest and highest disease duration quartiles; disease duration is calculated from date of diagnosis of HS. [**a**] Hurley stage II; [**b**] Hurley stage III. BKZ: bimekizumab; HiSCR: HS Clinical Response; HiSCR90/100: ≥90/100% reduction from baseline in total abscess and inflammatory nodule count with no increase from baseline in abscess or draining tunnel count; HS: hidradenitis suppurativa; ITP: initial treatment period; MTP: maintenance treatment period; OC: observed case.

CONCLUSIONS

Regardless of disease duration and severity, patients treated with bimekizumab demonstrated clinically meaningful efficacy at Year 1, with improvements to Year 3.

Bimekizumab-treated patients with shorter disease duration and moderate HS had higher achievement of each HiSCR threshold (HiSCR50/75/90/100) than those with longer duration and severe HS, especially at higher HiSCR thresholds.

These data suggest that earlier treatment with bimekizumab, when disease is less severe, leads to greater clinical response in patients with HS. These findings are consistent with the 'window of opportunity' concept in HS.

Author Contributions: Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: **RC, AA, VYS, HHZ, MG, TM, CCZ, TO, CC, NT, RS**; Drafting of the publication, or reviewing it critically for important intellectual content: **RC, AA, VYS, HHZ, MG, TM, CCZ, TO, CC, NT, RS**; Final approval of the publication: **RC, AA, VYS, HHZ, MG, TM, CCZ, TO, CC, NT, RS**.

Disclosures: RC: Served as an advisor, consultant, speaker, and/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Argenx, Astria Therapeutics, Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Forte Biosciences, Galderma, Genentech, GSK, Incyte, Imagene Bio Inc., Johnson & Johnson, Kenvue, Kowa Pharmaceuticals America, LEO Pharma, L'Oréal, Nektar Therapeutics, Nia Health, Novartis, Opsidio, Organon, Pfizer, RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, UCB, and Zai Lab. **AA:** On the Board of Directors for the Hidradenitis Suppurativa Foundation; received grants from: Hidradenitis Suppurativa Foundation, La Roche-Posay, and National Institutes of Health; served as consultant for AbbVie, Almirall, Avalo, Boehringer Ingelheim, Cantargia, Dragonfly Dx Incyte, InflaRx, LEO Pharma, Kymera, Navigator, Novartis, Oruka, Otsuka, Sanofi, and UCB; principal investigator for Boehringer Ingelheim and Processa; serves as the chair of the independent data monitoring committee for Almirall, InflaRx, and Zura Bio. **VYS:** On the board of directors for the Hidradenitis Suppurativa Foundation e.V. (HSF); advisor for the National Eczema Association; shareholder of Learn Health; has served as an advisory board member, investigator, speaker, and/or received research funding from AbbVie, Altus Lab/cQuell, Alumis, Aristea Therapeutics, Boehringer Ingelheim, Burt's Bees, Dermira, Eli Lilly and Company, Galderma, Genentech, GpSkin, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, MYOR, Novartis, Pfizer, Polyfins Technology, Regeneron, Sanofi Genzyme, Skin Actives Scientific, Sun Pharma, Target PharmaSolutions, and UCB. **HHZ:** Consultant for AbbVie, Incyte, InflaRx, Insmed, Novartis, and UCB. **MG**: Investigator, speaker, consultant or advisory board member for AbbVie, Acelyrin, Akros, Alumis, Amgen, AnaptysBio, Arcutis, Aristea, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Galderma, GSK, Incyte, JAMP Pharma, Janssen, Kyowa Kirin, L'Oréal, MedImmune, Meiji, MoonLake Immunotherapeutics, Nektar Therapeutics, Nimbus, Novartis, Oruka, Pfizer, Q32 Bio, Regeneron, Reistone, Sanofi, Sun Pharma, Takeda, Tarsus, UCB, Union, Ventyx, and Vyne. **TM:** Advisor, consultant, speaker, and/or investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, ONO Pharma, and UCB. **CCZ:** Received institution grants as a clinical and research investigator for AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Brandenburg Medical School Theodor Fontane, EADV, European Union, German Federal Ministry of Education and Research, GSK, Incyte, InflaRx, MSD, Novartis, Relaxera, Sanofi, and UCB; received honoraria as a consultant for AccureAcne, Almirall, Biogen, Boehringer Ingelheim, Commonwealth Serum Laboratories Behring, Eli Lilly and Company, Estée Lauder, Idorsia, Incyte, L'Oréal, MSD, NAOS-BIODERMA, Novartis, Pfizer, PPM, Sanofi, ShiRhom, Takeda, UCB, and ZuraBio; received lecture fees from Almirall, Amgen, Biogen, Bristol Myers Squibb, NAOS-BIODERMA, L'Oréal, Novartis, Pfizer, and UCB; President of the EHSF e.V., and the Deutsches Register Morbus Adamantiades-Behçet e.V.; board member of the International Society for Behçet's Disease; coordinator of the ALLOCATE Skin group of the ERN Skin; chair of the ARHS Task Force group of the EADV; editor of the EADV News; co-copyright holder of IHS4 on behalf of the EHSF e.V. **TO, CC, NT:** Employees and shareholders of UCB. **RS:** Received research grants or clinical trial contracts from AbbVie, Boehringer Ingelheim, Celgene/Amgen, Celgene/Bristol Myers Squibb, Charité Research Organization, CSL Behring, ICON, IQVIA RDS, Incyte, Janssen, MoonLake Immunotherapeutics, Novartis, Parexel, Rheinischen Friedrich-Wilhelms-Universität Bonn, Sanofi Aventis, TFS, and UCB; received honoraria for lectures, consulting, or participation in advisory boards from AbbVie, Almirall Hermal, Amgen, Bayer Schering Pharma, Bruno Bloch Stiftung, Janssen, Novartis, UCB, Universitätsmedizin Greifswald, and Wundnetz Berlin-Brandenburg; member of the International Psoriasis Council and speaker of psoriasis group of the German Consortium for Dermatological Research.

Acknowledgments: These studies were funded by UCB. We would like to thank the patients and their caregivers in addition to all the investigators and their teams who contributed to these studies. The authors acknowledge Susanne Wiegratz, UCB, Monheim am Rhein, Germany, for publication coordination, and Sarah Johnson, MSci, Costello Medical, Manchester, UK for medical writing support and editorial assistance. All costs associated with development of this presentation were funded by UCB.

HiSCR: Hidradenitis Suppurativa Clinical Response; HiSCR50/75/90/100: ≥50/75/90/100% reduction from baseline in total abscess and inflammatory nodule count with no increase from baseline in abscess or draining tunnel count; HS: hidradenitis suppurativa.